Sol-Gel’s Q2 2024 financials show a net income but ongoing revenue misses and underperformance in prior quarters. Despite positive updates on their drug pipeline and new licensing agreements, the consistent lag in revenue estimates makes SLGL a strong candidate for a short position due to potential near-term declines.